GGrantIndex
← Search

PHASE I PHARMACOKINETIC STUDY OF BCH 4556

$16,409M01FY2000RRNIH

University Of Texas Hlth Sci Ctr San Ant, San Antonio TX

Investigators

Linked publications & trials

Abstract

The primary objective of this study is to determine the maximum tolerated dose of BCH 4556, one of a category of compounds called L-enantiomers. The drug will be infused over 30 minutes for five consecutive days every three weeks. Quantitative and qualitative toxicities and their reversibility will be determined and the pharmacokinetic behavior of the drug will be described.

View original record on NIH RePORTER →